JP5960253B2 - ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤 - Google Patents

ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤 Download PDF

Info

Publication number
JP5960253B2
JP5960253B2 JP2014513717A JP2014513717A JP5960253B2 JP 5960253 B2 JP5960253 B2 JP 5960253B2 JP 2014513717 A JP2014513717 A JP 2014513717A JP 2014513717 A JP2014513717 A JP 2014513717A JP 5960253 B2 JP5960253 B2 JP 5960253B2
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
azaphosphinan
oxide
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014513717A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014516989A (ja
JP2014516989A5 (https=
Inventor
ワン シェン，
ワン シェン，
ジャック マウン，
ジャック マウン，
エイミン ジャン，
エイミン ジャン，
シャオリン ジェン，
シャオリン ジェン，
Original Assignee
ニューゲン セラピューティクス， インコーポレイテッド
ニューゲン セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューゲン セラピューティクス， インコーポレイテッド, ニューゲン セラピューティクス， インコーポレイテッド filed Critical ニューゲン セラピューティクス， インコーポレイテッド
Publication of JP2014516989A publication Critical patent/JP2014516989A/ja
Publication of JP2014516989A5 publication Critical patent/JP2014516989A5/ja
Application granted granted Critical
Publication of JP5960253B2 publication Critical patent/JP5960253B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014513717A 2011-05-31 2012-05-31 ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤 Active JP5960253B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161491851P 2011-05-31 2011-05-31
US61/491,851 2011-05-31
PCT/US2012/040304 WO2012166983A1 (en) 2011-05-31 2012-05-31 Tricyclic inhibitors of poly(adp-ribose)polymerase

Publications (3)

Publication Number Publication Date
JP2014516989A JP2014516989A (ja) 2014-07-17
JP2014516989A5 JP2014516989A5 (https=) 2015-07-16
JP5960253B2 true JP5960253B2 (ja) 2016-08-02

Family

ID=47259874

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014513717A Active JP5960253B2 (ja) 2011-05-31 2012-05-31 ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤

Country Status (8)

Country Link
US (4) US20140221314A1 (https=)
EP (2) EP2714703B1 (https=)
JP (1) JP5960253B2 (https=)
CN (1) CN103717609B (https=)
CA (1) CA2875025C (https=)
ES (1) ES2871052T3 (https=)
TW (1) TWI577693B (https=)
WO (1) WO2012166983A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2714703B1 (en) 2011-05-31 2021-03-10 Newgen Therapeutics, Inc. Tricyclic inhibitors of poly(adp-ribose)polymerase
PL2938598T3 (pl) 2012-12-31 2017-05-31 Cadila Healthcare Limited Podstawione pochodne ftalazyn-1 (2H)-onu jako selektywne inhibitory polimerazy-1 poli(ADP-rybozy)
US10562886B2 (en) 2015-05-21 2020-02-18 The Regents Of The University Of California Anti-cancer compounds
HUE066216T2 (hu) 2016-06-24 2024-07-28 Univ California Ftalazin származékok, mint a parp1, parp2 és/vagy tubulin inhibitorai, hasznosak a rák kezelésében
CA3095709A1 (en) * 2018-04-05 2019-10-10 Noviga Research Ab Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer
EP4013749B1 (en) 2019-08-15 2026-03-11 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
CN112574122B (zh) * 2019-09-27 2024-05-31 上海天慈国际药业有限公司 一种奥拉帕尼关键中间体的制备方法
CN114276301B (zh) * 2020-09-27 2025-04-01 江西科睿药业有限公司 Parp抑制剂的中间体化合物及其制备方法和应用
CN112624981B (zh) * 2021-03-09 2021-05-25 南京桦冠生物技术有限公司 一种2-氟-5-[(4-氧代-3h-2,3-二氮杂萘基)甲基]苯甲酸的制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1186606T4 (da) 1995-11-17 2011-12-05 Biotechnolog Forschung Gmbh Epothilonderivater, deres fremstilling og anvendelse
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
CN1345334A (zh) 1999-01-29 2002-04-17 伊姆克罗尼系统公司 对kdr特异的抗体及其应用
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
EP1187633A4 (en) 1999-04-08 2005-05-11 Arch Dev Corp USE OF ANTI-VEGF ANTIBODIES TO ENHANCE RADIATION IN ANTICANCER THERAPY
US7151102B2 (en) * 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
PL223343B1 (pl) 2000-10-30 2016-10-31 Kudos Pharm Ltd Zastosowanie związku, kompozycja farmaceutyczna zawierająca związek oraz pochodne ftalazynonowe
RU2292337C2 (ru) 2002-02-19 2007-01-27 Оно Фармасьютикал Ко., Лтд. Конденсированные производные пиридазина и лекарственные препараты, содержащие данные соединения в качестве активного ингредиента
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
BRPI0408284B8 (pt) * 2003-03-12 2021-05-25 Kudos Pharm Ltd compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos
CA2577191A1 (en) * 2004-08-26 2006-03-02 Kudos Pharmaceuticals Limited 4-heteroarylmethyl substituted phthalazinone derivatives
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
EP2049124A4 (en) 2006-07-20 2010-02-10 Merck & Co Inc PHOSPHOR DERIVATIVES AS HISTONDEACETYLASE HEMMER
DK2120579T3 (da) 2006-12-28 2014-02-03 Abbvie Inc Inhibitorer af poly(ADP-ripose)polymerase
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
US20080280910A1 (en) 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
TW200900396A (en) 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
US20090023727A1 (en) 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
MX2010002749A (es) 2007-09-14 2010-06-25 Astrazeneca Ab Derivados de ftalazinona.
CA2702429A1 (en) * 2007-10-17 2009-04-23 Kudos Pharmaceuticals Limited Crystalline form l 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
ES2524787T3 (es) 2007-11-15 2014-12-12 Msd Italia S.R.L. Derivados de piridazinona como inhibidores de PARP
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
PT2300013T (pt) * 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
CN102459258B (zh) * 2009-06-05 2015-11-25 赛福伦公司 1,2,4-三唑并[1,5a]吡啶衍生物的制备和用途
SG177451A1 (en) 2009-07-02 2012-02-28 Newgen Therapeutics Inc Phosphorus containing quinazoline compounds and methods of use
EP2714703B1 (en) 2011-05-31 2021-03-10 Newgen Therapeutics, Inc. Tricyclic inhibitors of poly(adp-ribose)polymerase

Also Published As

Publication number Publication date
US20230027257A1 (en) 2023-01-26
EP2714703A4 (en) 2014-12-31
US20140221314A1 (en) 2014-08-07
JP2014516989A (ja) 2014-07-17
TW201311713A (zh) 2013-03-16
EP2714703B1 (en) 2021-03-10
CN103717609B (zh) 2016-05-11
CN103717609A (zh) 2014-04-09
US20200299315A1 (en) 2020-09-24
EP2714703A1 (en) 2014-04-09
ES2871052T3 (es) 2021-10-28
EP3925962A1 (en) 2021-12-22
US11248013B2 (en) 2022-02-15
CA2875025C (en) 2021-08-03
US20170057984A1 (en) 2017-03-02
WO2012166983A1 (en) 2012-12-06
US20180094010A1 (en) 2018-04-05
CA2875025A1 (en) 2012-12-06
TWI577693B (zh) 2017-04-11

Similar Documents

Publication Publication Date Title
JP5960253B2 (ja) ポリ（ａｄｐ−リボース）ポリメラーゼの三環系阻害剤
CA3011189C (en) 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines
CN104822373B (zh) 治疗性化合物和组合物
JP5426544B2 (ja) ピリミジニル−ピリダジノン誘導体
JP6545199B2 (ja) ３−アミノ−１，５，６，７−テトラヒドロ−４ｈ−インドール−４−オン類
JP5756518B2 (ja) 複素環アルキニルベンゼン化合物と、その医療用組成物および使用
ES2550677T3 (es) Triazolopiridinas sustituidas y su uso como inhibidores de TTK
EP4026835A2 (en) Pd-1/pd-l1 inhibitors
UA123813C2 (uk) Заміщені індазоли, способи їх одержання, фармацевтичні препарати, які їх містять, та їх застосування для одержання лікарських засобів
JP2013529199A (ja) Ａｔｒキナーゼ阻害剤として有用な２−アミノピリジン誘導体
JP5005343B2 (ja) 急性及び／又は慢性神経障害の治療のためのｍＧｌｕＲ２アンタゴニストとＡＣｈＥインヒビターの併用
JP2013529643A (ja) Ａｔｒキナーゼ阻害剤として有用なピロロピラジン誘導体
JP2017526720A (ja) キナーゼ阻害剤としての化合物および組成物
JP2025535496A (ja) 化合物及びその使用
CN118055933A (zh) 选择性parp1抑制剂及其应用
JP2008523103A (ja) Ｅｒｋプロテインキナーゼのピリミジンインヒビターおよびその使用
JP2020503321A (ja) キナゾリン化合物並びにその調製方法、使用及び医薬組成物
CA3185491A1 (en) Atr inhibitors and uses thereof
US12612425B2 (en) Tricyclic inhibitors of poly(ADP-ribose)polymerase
HK40076587A (en) Pd-1/pd-l1 inhibitors
HK40029610B (zh) 一种哒嗪类衍生物抑制剂、其制备方法和应用
HK1177462A1 (en) Triazolopyridine derivatives
HK1142891B (en) Pyrimidinyl pyridazinone derivates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151102

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160428

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160524

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160622

R150 Certificate of patent or registration of utility model

Ref document number: 5960253

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250